Treatments for NAFLD: State of Art
Year: 2021
Type: review
Abstract: Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease in clinical practice and, consequently, a major health problem worldwide. It affects approximately 30% of adults in the general population and up to 70% of patients with type 2 diabetes (T2DM). Despite the current knowledge of the epidemiology, pathogenesis, and natural history of NAFLD, no specific pharmacological therapies are until now approved for this disease and, consequently, general strategies have been proposed to manage it. They include: (a) lifestyle change in order to promote weight loss by diet and physical activity, (b) control of the main cardiometabolic risk factors, (c) correction of all modifiable risk factors leading the development and progression of advanced forms of NAFLD, and (d) prevention of hepatic and extra-hepatic complications. In the last decade, several potential agents have been widely investigated for the treatment of NAFLD and its advanced forms-shedding some light but casting a few shadows. They include some glucose-lowering drugs (such as pioglitazone, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose co-transporter-2 (SGLT-2) inhibitors), antioxidants (such as vitamin E), statins or other lipid lowering agents, bile and non-bile acid farnesoid X activated receptor (FXR) agonists, and others. This narrative review discusses in detail the different available approaches with the potential to prevent and treat NAFLD and its advanced forms.
DOI: 10.3390/ijms22052350
Authors: Alessandro Mantovani, Andrea Dalbeni
Institution: Azienda Ospedaliera Universitaria Integrata Verona
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, NAFLD treatment, lifestyle modification, weight loss, type 2 diabetes, antidiabetic drugs, pioglitazone, GLP-1 receptor agonists, SGLT2 inhibitors, vitamin E, statins, lipid-lowering drugs, farnesoid X receptor agonist, cardiometabolic risk factors, hepatic complications
Open Access status: gold
Estimated APC paid: $2,160
OpenAlex ID: W3134320092
